CD274 and non-small cell lung carcinoma: Based on the outcome of the PACIFIC trial [10], the standard-of-care for treating unresectable locally advanced non-small cell lung cancer (NSCLC) has evolved to include consolidation anti-PD-L1 (monoclonal antibody targeted against programmed cell death-1 ligand 1 (PD-L1) ICI therapy, which conferred a clinically meaningful survival advantage when administered after chemoradiation [11].